Mode
Text Size
Log in / Sign up

Distinct genetic architectures and lung eQTLs differentiate mild from moderate-to-severe asthma phenotypesGenetic research identifies specific markers for mild and severe asthma

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that distinct genetic architectures and lung eQTLs are associated with different asthma severities.

This meta-analysis synthesizes genome-wide association study (GWAS) and expression quantitative trait loci (eQTL) data to map the genetic architecture of asthma. The analysis compared 14,372 individuals with mild asthma and 7,096 individuals with moderate-to-severe asthma against 28,816 non-asthma controls. The study identified shared susceptibility loci, including IL1RL1, IKZF3, and specific regions such as GTF3AP1-IL33 and HLA-DRB1-HLA-DQA1.

Distinct genetic signatures were identified for different severities. Mild asthma was associated with broader HLA class II signals and SMAD3, while moderate-to-severe asthma showed associations with WDR36 and PTCH1. Furthermore, lung eQTLs for moderate-to-severe asthma implicated TSLP, CAMK4, and FANCC, with enrichment in IL-13, IL-6, and IL-10 production. IL33 signals demonstrated a severity-gradient effect, showing stronger associations in moderate-to-severe cases.

The findings suggest potential for identifying novel therapeutic targets and support existing biologic targets. However, these results are based on genetic associations and do not establish direct causality or confirmed clinical targets. The study provides a framework for understanding the molecular diversity of asthma phenotypes.

How this fits prior evidence

This meta-analysis extends the understanding of asthma pathophysiology by identifying specific genetic markers for disease severity. It builds upon evidence that epigenetic mechanisms provide a molecular interface between genetic susceptibility and immune dysregulation in asthma. While the current study focuses on the genetic architecture of asthma phenotypes, the previous finding regarding epigenetic signatures suggests these may eventually serve as biomarkers for asthma endotyping and therapeutic stratification.

Living with asthma can feel like a constant battle against your own lungs. While many people share the same diagnosis, the experience of mild asthma can be very different from the daily struggle of moderate-to-severe cases. Researchers recently analyzed the genetic makeup of over 40,000 participants to understand why these conditions manifest so differently.

The study identified specific genetic markers that appear in both mild and severe cases, as well as unique markers that only appear in more severe forms. For example, certain genes related to inflammation and lung function were found in both groups, while others were specifically linked to the more intense symptoms of severe asthma. These differences suggest that the underlying biology of the disease changes as it becomes more severe.

While these findings are based on genetic associations rather than direct causes, they offer a clearer map of the disease. By identifying these specific pathways, scientists can better understand why some patients respond better to certain treatments. This research helps point toward new potential targets for medications, though these genes are currently candidates for future study rather than immediate clinical tools.

What this means for you:
Different types of asthma are linked to distinct genetic pathways, helping identify specific targets for future treatment.

Common questions

What did the study find about the genetics of asthma?

The study identified shared genetic markers for both mild and moderate-to-severe asthma, including the IL1RL1 and IKZF3 genes. It also found specific markers unique to moderate-to-severe asthma, such as WDR36 and PTCH1. These findings help map out the different biological pathways involved as asthma becomes more severe.

How does the study help with current asthma treatments?

By identifying specific genetic pathways and lung expression traits, the research supports existing biologic targets. It also highlights new candidate genes that could lead to different treatment options in the future. These findings help scientists understand the underlying biology of different asthma types.

Does this mean the study found a cure for asthma?

No, the study identifies genetic associations, not direct causes of asthma severity. The results highlight candidate genes and pathways that could lead to new treatments, but these are not yet confirmed as specific medical treatments or cures.

Study Details

Study typeMeta analysis
Sample sizen = 14,372
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Background: Moderate-to-severe asthma affects 15-30% of asthma patients, but accounts for over 50% of healthcare costs and disproportionate morbidity. However, the genetic mechanisms underlying moderate-to-severe versus mild asthma remain poorly understood. Methods: We performed separate pooled multi-ancestry GWAS of mild (N = 14,372) and moderate-to-severe asthma (N = 7,096) versus non-asthma controls (N = 28,816) among adult participants in the NIH All of Us Research Program (version 8). European, African, and Latino/admixed ancestry-specific GWAS were combined using fixed-effect meta-analysis. Lung expression quantitative trait loci (eQTL) and pathway analyses were performed to identify candidate genes and biological pathways across asthma phenotypes. Results: Mild and moderate-to-severe asthma shared susceptibility loci at IL1RL1, IKZF3, and the GTF3AP1-IL33, GTF3AP1-RANBP6, LINC02757-EMSY and HLA-DRB1-HLA-DQA1 regions. Shared lung eQTLs implicated IL18R1, IL18RAP, HLA genes, IL33, LRRC32, GRB7, MIEN1 and GSDMB. In contrast, the phenotypes exhibited distinct genetic architectures. Mild asthma was characterized by broader HLA class II signals and associations at SMAD3 and GSDMB, with enrichment of antigen presentation, T-helper cell differentiation, and TGF-{beta} regulation, consistent with adaptive immune mechanisms. Moderate-to-severe asthma was characterized by WDR36 and PTCH1, with lung eQTLs implicating TSLP, CAMK4, and FANCC. Pathway analysis identified enrichment of IL-13, IL-6, and IL-10 production, myeloid leukocyte differentiation, and oxidative stress responses, consistent with innate inflammation and pathways implicated in steroid resistance. The IL33 signals showed a severity-gradient effect, with stronger associations in moderate-to-severe asthma. Conclusion: Mild and moderate-to-severe asthma exhibit shared and distinct genetic architectures that support existing biologic targets and suggest novel therapeutic candidates.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.